News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Complexa, Inc. Initiates First Clinical Trial Of CXA-10 for Acute Kidney Injury



5/1/2014 2:07:53 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PITTSBURGH--(BUSINESS WIRE)--Complexa, Inc., an inflammatory and metabolic disease-focused biopharmaceutical company announced today that it has initiated the first human clinical trial of lead product candidate CXA-10. The initial target indication is for the treatment of acute kidney injury related to the administration of contrast imaging agents in high-risk patients. This Phase I trial is designed to assess CXA-10’s safety and pharmacokinetics. Through the use of various biomarkers, the study will also demonstrate CXA-10’s mechanism of action and document target organ engagement that will further illuminate its regulation of critical inflammatory pathways.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES